Abstract
Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels. This may induce rapid bone loss. Tamoxifen is a partial oestrogen receptor agonist and antagonist (classified as a selective oestrogen receptor modulator or SERM). As it has agonistic effects on oestrogen receptors of bone it increases bone mineral density and thus may potentially prevent fractures. In contrast aromatase inhibitors such as anastrozole lead to a decrease in bone mineral density and an increased risk of fractures. Most high-dose intravenous chemotherapeutic regimens induce rapid bone loss from effects on the gonads with induction, for example, of premature menopause. Low-dose oral agents such as methotrexate are not associated with an increased risk of fractures. Androgen deprivation therapies such as LHRH agonists in breast cancer are also associated with an increase in bone loss and an increased risk of fractures. With the increasing long-term survival of patients with cancer, preventive measures against osteoporosis must be considered.
Keywords: Skeletal Effects of Drugs, Cancer, sex steroid levels, Tamoxifen, bone mineral density, aromatase inhibitors, osteoporosis, antagonist
Current Drug Safety
Title: Skeletal Effects of Drugs to Treat Cancer
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Skeletal Effects of Drugs, Cancer, sex steroid levels, Tamoxifen, bone mineral density, aromatase inhibitors, osteoporosis, antagonist
Abstract: Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels. This may induce rapid bone loss. Tamoxifen is a partial oestrogen receptor agonist and antagonist (classified as a selective oestrogen receptor modulator or SERM). As it has agonistic effects on oestrogen receptors of bone it increases bone mineral density and thus may potentially prevent fractures. In contrast aromatase inhibitors such as anastrozole lead to a decrease in bone mineral density and an increased risk of fractures. Most high-dose intravenous chemotherapeutic regimens induce rapid bone loss from effects on the gonads with induction, for example, of premature menopause. Low-dose oral agents such as methotrexate are not associated with an increased risk of fractures. Androgen deprivation therapies such as LHRH agonists in breast cancer are also associated with an increase in bone loss and an increased risk of fractures. With the increasing long-term survival of patients with cancer, preventive measures against osteoporosis must be considered.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Skeletal Effects of Drugs to Treat Cancer, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699522
DOI https://dx.doi.org/10.2174/157488608785699522 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Biomarkers Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Strategies for the Preparation of Bifunctional Gadolinium(III) Chelators
Current Organic Synthesis Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Screening and Identification of Differentially Expressed Genes Between Diabetic Nephropathy Glomerular and Normal Glomerular via Bioinformatics Technology
Combinatorial Chemistry & High Throughput Screening Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship
Current Medicinal Chemistry CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine